Loading provider…
Loading provider…
Infectious Disease Physician in Charlottesville, VA
NPI: 1265648547Primary Practice Location
UNIVERSITY OF VIRGINIA MEDICAL CENTER
1215 Lee St, Charlottesville, VA
Primary Employer
UVA Physicians Group
virginia.edu
HQ Phone
Get M.D., M.P.H. Scott's Phone Numberphone_androidMobile
Get M.D., M.P.H. Scott's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCT State Medical License
VA State Medical License
Oregon Health and Science University School of Medicine
Medical School
Until 2004
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 58 | 166 |
| 2 | 99223Initial hospital inpatient care, typically 70 minutes per day | 35 | 35 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 34 | 60 |
| 4 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 15 | 15 |
| 5 | 99239Hospital discharge day management, more than 30 minutes | 13 | 13 |
Intestinal Parasitic Infections May Be Overlooked Drivers of the Tuberculosis Pandemic.
Authors: Steel, Lili B, Narasimhan, Prakash Babu, Chaudhari, Megha, Dauphinais, Madolyn R, Huang, Samantha, Beall, Kaley, Carwile, Madeline E, Cintron, Chelsie, Du, Xinyi, Heysell, Scott K, Lakshminarayanan, Subitha, Singh, Urvashi B, Sinha, Pranay
Journal: Am J Trop Med Hyg
Publication Date: 2024-08-13
Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.
Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa.
Authors: Gerald Friedland, Neel Gandhi, Palav Babaria
Journal: Emerg Infect Dis
Lead Sponsor: University of Virginia
Intervention / Treatment: DRUG: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma